P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence

Published: 23 February 2021

  • Views:

    Views Icon 32547
  • Likes:

    Heart Icon 11

Overview

Full programme

  • Views:

    Views Icon 32547
  • Likes:

    Heart Icon 11

Overview

A roundtable to discuss the current evidence for P2Y12 inhibitor use in NSTE-ACS

The European Heart Association’s guideline update on NSTE-ACS management in 2020 took into consideration several landmark trials, which ultimately changed the level of recommendation on key aspects of antiplatelet use, in both pre- and post-PCI practice. This roundtable, led by Prof Dominick Angiolillo, considers the main updates, the data underpinning the changes and what they mean for real-world practice through expert discourse and case examination.

 

*Submit your questions to the faculty by clicking on the 'Q&A' button to the right of the screen. Your questions will be answered by the faculty and shared as a final chapter of the NSTEMI roundtable. 

This independent medical education programme is supported by an unrestricted educational grant from AstraZeneca. AstraZeneca has no involvement in the organisation of the programme.

Learning Objectives

  • Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
  • Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
  • Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case

Series overview

Part 1

Chapter 1

Here, the faculty will provide an overview of recent changes to ESC guidelines on P2Y12 treatment pre- and post-intervention.

1 session

Part 2

Chapter 2

In this chapter the faculty review clinical data that have shaped current ESC recommendations. The faculty describe pivotal trials including PLATO, TRITON-TIMI, ACCOAST and ISAR-REACT 5.

1 session

Part 3

Chapter 3

In this chapter the faculty hold an open discussion on new recommendations around pre-treatment and choice of agent.

1 session

Part 4

Chapter 4

In this chapter, Prof Angiolillo presents hypothetical cases for the faculty to discuss.

1 session

Part 5

Chapter 5

In this final chapter, the faculty will review and answer the questions asked by the viewers.

1 session

Faculty biographies